| Literature DB >> 27571712 |
Hirotaka Matsuo1, Tomoyuki Tsunoda2, Keiko Ooyama3, Masayuki Sakiyama1,4, Tsuyoshi Sogo2, Tappei Takada5, Akio Nakashima6, Akiyoshi Nakayama1, Makoto Kawaguchi1,7, Toshihide Higashino1, Kenji Wakai8, Hiroshi Ooyama3, Ryota Hokari9, Hiroshi Suzuki5, Kimiyoshi Ichida6,10, Ayano Inui2, Shin Fujimori11, Nariyoshi Shinomiya1.
Abstract
To clarify the physiological and pathophysiological roles of intestinal urate excretion via ABCG2 in humans, we genotyped ABCG2 dysfunctional common variants, Q126X (rs72552713) and Q141K (rs2231142), in end-stage renal disease (hemodialysis) and acute gastroenteritis patients, respectively. ABCG2 dysfunction markedly increased serum uric acid (SUA) levels in 106 hemodialysis patients (P = 1.1 × 10(-4)), which demonstrated the physiological role of ABCG2 for intestinal urate excretion because their urate excretion almost depends on intestinal excretion via ABCG2. Also, ABCG2 dysfunction significantly elevated SUA in 67 acute gastroenteritis patients (P = 6.3 × 10(-3)) regardless of the degree of dehydration, which demonstrated the pathophysiological role of ABCG2 in acute gastroenteritis. These findings for the first time show ABCG2-mediated intestinal urate excretion in humans, and indicates the physiological and pathophysiological importance of intestinal epithelium as an excretion pathway besides an absorption pathway. Furthermore, increased SUA could be a useful marker not only for dehydration but also epithelial impairment of intestine.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27571712 PMCID: PMC5004129 DOI: 10.1038/srep31003
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Genotyping results for each estimated ABCG2 function of participants.
| Estimated ABCG2 function | Rs72552713 (Q126X) | Rs2231142 (Q141K) | Diplotype | Number of participants | ||
|---|---|---|---|---|---|---|
| Hemodialysis | Health examination | Acute gastroenteritis | ||||
| Full function | C/C | C/C | *1/*1 | 51 | 50 | 29 |
| 3/4 function | C/C | C/A | *1/*2 | 46 | 41 | 30 |
| 1/2 function | C/C | A/A | *2/*2 | 4 | 8 | 7 |
| C/T | C/C | *1/*3 | 3 | 5 | 1 | |
| ≤1/4 function | C/T | A/C | *2/*3 | 2 | 2 | 0 |
| T/T | C/C | *3/*3 | 0 | 0 | 0 | |
| Total | 106 | 106 | 67 | |||
**1, *2 and *3 represent haplotypes “C-C” (126Q and 141Q), “C-A” (126Q and 141K) and “T-C” (126X and 141Q) of two dysfunctional variants, Q126X (rs72552713) and Q141K (rs2231142), respectively.
†106 health examination participants were matched for sex- and body-mass index to 106 hemodialysis patients and selected from J-MICC Study.
Estimated ABCG2 function and SUA of hemodialysis patients and acute gastroenteritis patients.
| Estimated ABCG2 function (Diplotype of Q126X and Q141K) | Hemodialysis | Acute gastroenteritis | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Case | Control | Acute period | Recovery period | |||||||||
| N | SUA (mg/dl) | β (SEM) | N | SUA (mg/dl) | β (SEM) | N | SUA (mg/dl) | β (SEM) | N | SUA (mg/dl) | β (SEM) | |
| Full function (*1/*1) | 51 | 7.1 ± 0.1 | 50 | 5.3 ± 0.2 | 29 | 7.5 ± 0.5 | 24 | 4.2 ± 0.3 | ||||
| 3/4 function (*1/*2) | 46 | 7.9 ± 0.1 | 41 | 5.0 ± 0.2 | 30 | 9.6 ± 0.7 | 24 | 4.9 ± 0.4 | ||||
| ≤1/2 function (*1/*3, *2/*2, *2/*3 or *3/*3) | 9 | 8.4 ± 0.7 | 15 | 6.0 ± 0.3 | 8 | 10.6 ± 1.4 | 7 | 5.4 ± 0.6 | ||||
| Total | 106 | 7.5 ± 0.1 | 0.63 (0.16) | 106 | 5.3 ± 0.1 | 0.17 (0.18) | 67 | 8.8 ± 0.4 | 1.73 (0.61) | 55 | 4.7 ± 0.2 | 0.60 (0.36) |
N, number; SUA, serum uric acid.
Plus-minus values are means ± SEM.
**1, *2 and *3 represent haplotypes of two dysfunctional variants (Q126X and Q141K) as previously reported. Detailed information on ABCG2 haplotypes is also shown in Table 1.
†106 controls were matched for sex- and body-mass index to 106 hemodialysis patients and selected from health examination participants in J-MICC Study.
‡β means regression coefficient.
§P values were obtained by multiple regression analysis including ABCG2 function and age in the model.
||P values were obtained by linear regression analysis.
Dehydration in acute gastroenteritis patients for each ABCG2 function.
| Estimated ABCG2 function (Diplotype of Q126X and Q141K) | Number | |||
|---|---|---|---|---|
| Acute gastroenteritis | Dehydration | |||
| − | + | |||
| Full function (*1/*1) | 29 | 23 | 6 | |
| 3/4 function (*1/*2) | 30 | 20 | 10 | |
| ≤1/2 function (*1/*3, *2/*2, *2/*3 or *3/*3) | 8 | 6 | 2 | |
| Total | 67 | 49 | 18 | 0.50 |
**1, *2 and *3 represent haplotypes of two dysfunctional variants (Q126X and Q141K). Detailed information on ABCG2 haplotypes is also shown in Table 1.
†“−” means minimal or no dehydration and “+” means mild to moderate or severe dehydration evaluated according to the criteria recommended by the Center for Disease Control (CDC).
‡P values were obtained by Cochran-Armitage test.
Figure 1Pathophysiological model of ABCG2-mediated urate excretion in end-stage renal disease and acute gastroenteritis patients.
SUA, serum uric acid. ABCG2 physiologically mediates urate excretion in both intestine and kidney. In end-stage renal disease (renal failure) patients, renal urate excretion would be nearly eliminated with urate excretion depending almost entirely on intestinal excretion. Thus, the degree of intestinal ABCG2 dysfunction strongly affects the severity of hyperuricemia in renal diseases such as end-stage renal disease. On the other hand, in acute gastroenteritis patients, intestinal inflammation seriously impairs the intestinal urate excretion via ABCG2. Therefore, the degree of renal ABCG2 dysfunction markedly affects the severity of hyperuricemia in intestinal diseases such as acute gastroenteritis patients.